Collection of mononuclear cells in the Spectra for the generation of dendritic cells

Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture

“…According to previous studies, the modification of program settings to reduce residual PLTs of components did not result in a relevant difference of monocyte yields 11,12 . The mean monocyte yield in the present series was comparable to data published previously (2‐3 × 10 9 CD14+ cells/bag) 12,20 .…”

“…A total of 50 leukapheresis procedures obtained by Spectra were enrolled in this study. We applied a modified MNC program using a reduced separation factor (SF) of 250 (Fresenius ASTEC 204: MNC, version 5.1) 11,12 . The inlet blood flow was 50 mL per minute with a continuous collection rate (CR) of 1.0 mL per minute.…”

Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma

“…Our aim for the starting population for in vitro cultivation of DCs was to collect a maximum of MNCs and a minimum of platelets. Recently, we reported that this could be achieved in healthy donors who donated MNC concentrates by the Spectra MNC program with a low SF of 250 12 . The AS.TEC 204 also offers the opportunity of a reduced centrifuge velocity in the MNC program by reducing the CP from 212 to 141.…”

“…For 12 apheresis procedures, we used the Spectra cell separator with the WBC set and the MNC program. The standard separation factor (SF) of 500 was reduced to 250 to lessen platelet contamination 12 . The plasma pump rate was set by visual inspection of the collection line to allow a product Hct of approximately 5 percent.…”

Transcript profiling of human dendritic cells maturation‐induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma

“…All materials and reagents used for the apheresis and DC culture were sterile and/or endotoxin free (< 0.5 Limulus amebocyte lysate U/ml) and approved by the Federal Drug Administration (FDA) for human use with the exception of the plastic beads, IL‐4 and Nycoprep media. The MNC products were harvested on a Spectra apheresis system (Spectra, COBE BCT, Lakewood, CO, USA) using the cell collection programme previously described (Glaser et al , 1999). These products were additionally purified by buoyant density centrifugation over Nycoprep 1068 media (Boyum, 1983).…”